β 1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy

Journal of Clinical Investigation

Volumn 122, Issue 4, 2012, Pages 1529-1540

  Eke, Iris ^a   Deuse, Yvonne ^a   Hehlgans, Stephanie ^a,b   Gurtner, Kristin ^a   Krause, Mechthild ^a   Baumann, Michael ^a   Shevchenko, Anna ^c   Sandfort, Veit ^a   Cordes, Nils ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CORTACTIN; FOCAL ADHESION KINASE 1; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD29; CARCINOMA, SQUAMOUS CELL; CORTACTIN; FEMALE; FOCAL ADHESION KINASE 1; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84859598676     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61350     Document Type: Article

References (57)

1. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008;8(7):545-554. (Pubitemid 351881850)
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2010;144(5):646-674.
3. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517-531. (Pubitemid 351881844)
4. Gerber DE, Minna JD. ALK inhibition for nonsmall cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2011;18(6):548-551.
5. Krause M, Gurtner K, Deuse Y, Baumann M. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Biol. 2009; 85(11):943-954.
6. Sawyers C. Targeted cancer therapy. Nature. 2004; 432(7015):294-297. (Pubitemid 39551656)
7. Bonner JA, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578. (Pubitemid 43209104)
8. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets. 2002;2(1):37-43. (Pubitemid 34627377)
9. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
10. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007; 1775(1):163-180. (Pubitemid 44881199)
11. Ruegg C, Alghisi GC. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res. 2010;180:83-101.
12. Weaver VM, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2002; 2(3):205-216. (Pubitemid 41043976)
13. Eriksen JG, Steiniche T, Sogaard H, Overgaard J. Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. Apmis. 2004; 112(9):560-568. (Pubitemid 40040183)
14. Yao ES, et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67(2):659-664. (Pubitemid 46192205)
15. Janes SM, Watt FM. New roles for integrins in squamous-cell carcinoma. Nat Rev Cancer. 2006; 6(3):175-183. (Pubitemid 43292561)
16. Cordes N, Seidler J, Durzok R, Geinitz H, Brakebusch C. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation- induced genotoxic injury. Oncogene. 2006; 25(9):1378-1390. (Pubitemid 43336466)
17. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687. (Pubitemid 35283958)
18. Moser M, Legate KR, Zent R, Fassler R. The tail of integrins, talin, and kindlins. Science. 2009; 324(5929):895-899.
19. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A. 2009;106(25):10290-10295.
20. Ramirez NE, et al. The alphabeta integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest. 2010;121(1):226-237.
21. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008;68(11):4398-4405.
22. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-674.
23. Eke I, et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest. 2010;120(7):2516-2527.
24. Legate KR, Fassler R. Mechanisms that regulate adaptor binding to beta-integrin cytoplasmic tails. J Cell Sci. 2009;122(pt 2):187-198.
25. Kasahara T, Koguchi E, Funakoshi M, Aizu-Yokota E, Sonoda Y. Antiapoptotic action of focal adhesion kinase (FAK) against ionizing radiation. Antioxid Redox Signal. 2002;4(3):491-499. (Pubitemid 34753389)
26. Lim ST, Mikolon D, Stupack DG, Schlaepfer DD. FERM control of FAK function: implications for cancer therapy. Cell Cycle. 2008;7(15):2306-2314.
27. Sood AK, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120(5):1515-1523.
28. Yuan Z, Zheng Q, Fan J, Ai KX, Chen J, Huang XY. Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(10):1489-1496.
29. Cance WG, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 2000;6(6):2417-2423. (Pubitemid 30399210)
30. Owens LV, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55(13):2752-2755.
31. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2- dependent binding of pp60src. Mol Cell Biol. 1994; 14(3):1680-1688.
32. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117(pt 20):4619-4628. (Pubitemid 39433429)
33. Ng J, Luo L. Rho GTPases regulate axon growth through convergent and divergent signaling pathways. Neuron. 2004;44(5):779-793. (Pubitemid 39575632)
34. Liu S, Calderwood DA, Ginsberg MH. Integrin cytoplasmic domain-binding proteins. J Cell Sci. 2000; 113(pt 20):3563-3571.
35. Higgs HN, Pollard TD. Regulation of actin filament network formation through ARP2/3 complex: activation by a diverse array of proteins. Annu Rev Biochem. 2001;70:649-676. (Pubitemid 32662221)
36. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene. 2001;20(44):6418-6434. (Pubitemid 32977848)
37. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007; 67(9):4227-4235. (Pubitemid 46815069)
38. Shibata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol. 2004;164(6):2269-2278. (Pubitemid 38669372)
39. Schubert V, Dotti CG. Transmitting on actin: synaptic control of dendritic architecture. J Cell Sci. 2007; 120(pt 2):205-212.
40. Webb BA, Jia L, Eves R, Mak AS. Dissecting the functional domain requirements of cortactin in invadopodia formation. Eur J Cell Biol. 2007; 86(4):189-206. (Pubitemid 46404601)
41. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70(3):389-399.
42. Serrels B, et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol. 2007;9(9):1046-1056. (Pubitemid 47338144)
43. Jarvius J, et al. Digital quantification using amplified single-molecule detection. Nat Methods. 2006; 3(9):725-727. (Pubitemid 44275741)
44. Gabarra-Niecko V, Keely PJ, Schaller MD. Characterization of an activated mutant of focal adhesion kinase: 'SuperFAK'. Biochem J. 2002; 365(pt 3):591-603. (Pubitemid 34864441)
45. Lua BL, Low BC. BPGAP1 interacts with cortactin and facilitates its translocation to cell periphery for enhanced cell migration. Mol Biol Cell. 2004; 15(6):2873-2883. (Pubitemid 38691875)
46. Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2010;11(11):802-814.
47. Cordes N, Park CC. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol. 2007; 83(11-12):753-760. (Pubitemid 350219108)
48. Sugahara KN, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16(6):510-520.
49. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10(7):445-457.
50. Kim SA, Kwon SM, Kim JA, Kang KW, Yoon JH, Ahn SG. 5?-Nitro- indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin beta1/FAK/Akt signaling. Cancer Lett. 2011; 306(2):197-204.
51. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10(10):753-768.
52. Ricart AD, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14(23):7924-7929.
53. Estrugo D, Fischer A, Hess F, Scherthan H, Belka C, Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One. 2007;2(3):e269.
54. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56-68. (Pubitemid 40064899)
55. Morello V, et al. β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene. 2011;30(39):4087-4096.
56. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol. 1989; 109(2):877-889. (Pubitemid 19197045)
57. Zhang H, Shi X, Paddon H, Hampong M, Dai W, Pelech S. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J Biol Chem. 2004;279(34):35726-35734. (Pubitemid 39100577)